AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need
AstraZeneca reported Monday that adding Lynparza to Imfinzi improved outcomes in mismatch repair proficient endometrial cancer, more than doubling the median duration of response in patients.